Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288565 | 1.00 | NPSR1 (0.65) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL4205886 | 1.00 | NPSR1 (0.65) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL28855755 | 0.98 | NPSR1 (0.63) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL28912588 | 0.98 | NPSR1 (0.63) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL30000293 | 0.98 | NPSR1 (0.63) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL9717237 | 0.88 | NPSR1 (0.52) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL19592213 | 0.88 | NPSR1 (0.52) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL28020231 | 0.87 | NPSR1 (0.50) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL28020230 | 0.87 | NPSR1 (0.55) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 | |
| SCHEMBL20930309 | 0.84 | NPSR1 (0.56) | NPSR1HCAR2GLO1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-06-27 | — | — | US | disclosed |
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-117460731-A | Heterocyclic lactams, process for their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230309558-A1 | OXALOACETATE AND RELATED COMPOUNDS AS HERBICIDAL AGENTS | VERDESIAN LIFE SCIENCES U.S., LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230309558-A1 | OXALOACETATE AND RELATED COMPOUNDS AS HERBICIDAL AGENTS | VERDESIAN LIFE SCIENCES U.S., LLC | 2023-10-05 | — | — | US | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241794-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHEPALO ALTO LLC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1401826-B1 | PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2007020502-A2 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | NPSR1 3991/4885HCAR2 3490/4885GLO1 734/4885 |
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | REN, PKD1, SAV1 | NPSR1 2271/4885HCAR2 923/4885GLO1 2482/4885 |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | NPSR1 1376/4885HCAR2 838/4885GLO1 467/4885 |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | NPSR1 3509/4885HCAR2 979/4885GLO1 4054/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | NPSR1 3604/4885HCAR2 1023/4885GLO1 3261/4885 |
| US-20230309558-A1 | OXALOACETATE AND RELATED COMPOUNDS AS HERBICIDAL AGENTS | OAT, AGXT, OTC | NPSR1 4185/4885HCAR2 349/4885GLO1 19/4885 |
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | NPSR1 4786/4885HCAR2 4171/4885GLO1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.